Rimonabant
- Generic Name
- Rimonabant
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H21Cl3N4O
- CAS Number
- 168273-06-1
- Unique Ingredient Identifier
- RML78EN3XE
- Background
Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. It was rejected for approval for use in the United States. This decision was made after a U.S. advisory panel recommended the medicine not be approved because it may increase suicidal thinking and depression.
- Indication
For use in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m, or patients wih a BMI greater than 27 kg/m with associated risk factors, such as type 2 diabetes or dyslipidaemia.
- Associated Conditions
- -
- Associated Therapies
- -
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.